Eli Lilly: Mounjaro Needs To Catch Up In 2023 Summary The Eli Lilly and Company diabetes upstart was on fewer formularies than reported. Less coverage meant lower Eli Lilly and Company sales, contributing to a revenue miss in Q4. In oncology, a label expansion could continue the outperformance of Verzenio. ALIOUI Mohammed Elamine/iStock via […]
